Etiometry Expands AI Software Platform Portfolio with 2 New FDA-Cleared Algorithms for Managing Critical Care Patients
News and Press Releases
BOSTON, Mass. – July 12, 2022 – Etiometry, a leader in clinical decision-support software for critical care, announced today that it has doubled its FDA-cleared risk analytics portfolio to four indices, further strengthening its capability to track the fundamental pathways through which patients deteriorate under intensive care. Etiometry is the only critical care AI decision-support company with four FDA-cleared algorithms. The platform’s seven total FDA clearances demonstrate the scalability of its patented Risk Analytics Technology and its expanding ability to transform continuously acquired physiologic data into essential insights for clinical decision-making.
Assuring adequate tissue oxygenation and carbon dioxide ventilation are fundamental principles of critical care medicine. Etiometry’s previously cleared IDO2 and IVCO2 indices process the vast amounts of data generated by intensive care unit (ICU) patients to continuously detect subtle patient trends towards an adverse physiologic state, bringing timely awareness to clinicians and avoiding patient harm. To further enhance this capability, the newly FDA-cleared hyperlactatemia index (HLA) and acidemia index (ACD) use the same automatic data aggregation and computation model to track the downstream effects of inadequate oxygenation and ventilation.
Etiometry’s patented Risk Analytics Technology computes the four risk algorithms, utilizing models of human physiology to interpret patient-generated data into individualized risk assessments. The company has collected data from hospitals across the globe to compile a comprehensive database of more than 150M hours of patient physiologic signals driving continuous improvement of the physiologic modeling, leading to the development of the ACD and HLA indices. With each iteration and model improvement, Etiometry is scaling the technology to detect more pathways of patient deterioration, further strengthening the platform’s safety net for clinicians caring for critically ill patients.
“We are committed to modernizing clinical workflows by leveraging our team’s data science expertise and platform scalability to deliver clinical advancements that serve new markets,” said Shane Cooke, CEO of Etiometry. “The Etiometry platform’s FDA-cleared pediatric indices for ID02, IVC02, ACD, and HLA along with ID02 Index for adult patients are also authorized by Health Canada with additional regulatory approvals underway to serve more patient populations and markets.”
###
About Etiometry
Founded in 2010, Etiometry is a leader in clinical decision-support software designed to help clinicians in the intensive care setting make data-based decisions regarding their patients’ care and treatment. The company’s technologies provide valuable clinical insight and analysis to support early recognition of subtle changes in patients’ conditions to avoid complications and speed recovery. With roots in pediatric ICUs, Etiometry’s software is utilized in more than 20 of the top U.S. children’s hospitals and a growing number of top adult hospitals. Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering the cost of care through the more effective use of data. To learn more, visit www.etiometry.com.
We’d love to hear from you
Whether you’re curious about how Etiometry can help support your team, the platform’s latest outcomes data or a demo – we’re ready to answer your questions.
Contact UsRelated
The Documentation Gap Nobody Talks About — And What It’s Costing Your ICU
Every ICU has a documentation problem. Most don’t know the full scope of it. Clinical events happen continuously in high-acuity care — hemodynamic shifts, ventilatory changes, transient complications that resolve before the next chart entry. Clinicians respond to them. They manage through them. And then, in the relentless pace of the ICU, those events may […]
Beyond Escalation: How Clinical Intelligence Supports ICU De-Escalation Decisions
In high-acuity care, clinical attention naturally gravitates toward escalation: adding interventions, increasing support, responding to deterioration. But the other half of intensive care, knowing when and how to safely step back from those interventions, is equally demanding and equally consequential. Prolonged mechanical ventilation, extended vasoactive support, mechanical circulatory support (MCS) and delayed discharge carry real […]
Cardiogenic Shock in Cardiac Surgery Patients: Why Continuous Physiologic Data Matters
Cardiac surgery patients don’t come from a single mold. A valve repair patient, a transplant recipient, a CABG patient, and a patient recovering from aortic surgery each carry a different hemodynamic profile and a different trajectory through the ICU. What they share is vulnerability, particularly to one of the most dangerous complications in post-surgical critical […]